Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Kezar Life Sciences (KZR) Asset Writedowns and Impairment (2023 - 2025)

Kezar Life Sciences (KZR) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $900000.0 as the latest value for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $900000.0; the TTM value through Dec 2025 reached $2.4 million, down 42.86%, while the annual FY2025 figure was $900000.0, 41.9% down from the prior year.
Asset Writedowns and Impairment hit $900000.0 in Q4 2025 for Kezar Life Sciences, down from $1.5 million in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $2.7 million in Q4 2023 and bottomed at $900000.0 in Q4 2025.
Average Asset Writedowns and Impairment over 3 years is $1.7 million, with a median of $1.5 million recorded in 2024.